Farber C M, Benoit Y, Boven K, De Baets F, Ferster A, Hoyoux C, Mascart F, Otten J, Philippet P, Van Lierde S, Van Vooren J P, Vermylen C
Hôpital Erasme Unité de Traitement des Immunodéficiences Route de Lennik 808 1070 Bruxelles.
Rev Med Brux. 2001 Apr;22(2):73-82.
Severe primary immunodeficiencies (PID) are rare; their global incidence is comparable to that of childhood leukemia; they include more than 100 different entities. Clinical manifestations are: unusually severe or frequent infections or infections that do not respond to adequate treatment; an increased risk of certain malignancies; sometimes auto-immune manifestations. Delayed diagnosis and management of PID can lead to severe and irreversible complications or to death. PID can become manifest only in the adult; in common variable immune deficiency, the median age at diagnosis is between the 2nd and the 3rd decade of life. PID are often transmitted genetically; recent progresses in molecular biology have allowed more precise and earlier, including antenatal, diagnosis. Molecular treatment of 3 infants with a severe immunodeficiency has recently been achieved in April 2000. Those progresses were mostly based on the study of immunodeficiency databases. We present here the work of a Belgian group specialized in PID; meetings have started in June 1997. This group establishes guidelines for the diagnosis and treatment of PID, adapted to the local situation. The elaboration of a national register of PID is also underway; this has to provide all guaranties of anonymity to patients and families. Such a register already exists at the European level; it has provided the basis for new diagnostic and therapeutic possibilities. The inclusion of Belgian data in this register should allow essential progresses essential for our patients.
严重原发性免疫缺陷病(PID)较为罕见;其全球发病率与儿童白血病相当;包括100多种不同类型。临床表现为:异常严重或频繁的感染,或对适当治疗无反应的感染;某些恶性肿瘤风险增加;有时出现自身免疫表现。PID的诊断和治疗延迟可导致严重且不可逆的并发症甚至死亡。PID可能仅在成年期显现;在常见可变免疫缺陷中,诊断的中位年龄在生命的第二个和第三个十年之间。PID常具有遗传传递性;分子生物学的最新进展已使诊断更加精确和提早,包括产前诊断。2000年4月,最近对3名严重免疫缺陷婴儿实现了分子治疗。这些进展大多基于免疫缺陷数据库的研究。我们在此展示一个比利时PID专业小组的工作;会议于1997年6月开始。该小组制定了适合当地情况的PID诊断和治疗指南。全国PID登记册的编制工作也在进行中;这必须为患者和家庭提供所有匿名保障。欧洲层面已经存在这样一个登记册;它为新的诊断和治疗可能性提供了基础。将比利时的数据纳入该登记册应能为我们的患者带来至关重要的进展。